Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer

 
• By Sten Stovall

Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.

More from Anticancer

More from Therapy Areas